On April 23, 2024 Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, reported its participation in the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 27th Annual Meeting to be held in Baltimore, MD from May 7-11, 2024 (Press release, Factor Bioscience, APR 23, 2024, View Source;cell-therapy-asgct-27th-annual-meeting-302124039.html [SID1234642256]). Factor will deliver seven presentations, representing the company’s most expansive presentation of data to date.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"2024 marks the fifth year that Factor will present our latest data at the Annual Meeting of the ASGCT (Free ASGCT Whitepaper)," said Dr. Matt Angel, Co-Founder, Chairman and CEO of Factor. "This year promises to be particularly exciting, as we present our progress on deploying the powerful mRNA cell-engineering technologies that we have built at Factor over the last decade."
Dr. Kyle Garland, Director of Translational Science at Factor, commented, "We have been working hard over the last year to address several critical needs in our industry, including tissue-targeted delivery of nucleic acids, durable allogeneic cell therapies, and effective approaches for targeting solid tumors. We look forward to presenting our results in these and other areas next month at the ASGCT (Free ASGCT Whitepaper) Annual Meeting."
Details of the presentations are below:
"iMSCs Derived from mRNA-Engineered B2M-KO iPSCs Exhibit Enhanced Immunosuppressive Activity and Stealthing Features." -to be presented by Raven Hinkel on May 11 at 10:30 am, Novel Immune Effector Cell Manufacturing Oral Abstract Session, Ballroom 2.
"Sustained Transgene Expression in Engineered iPSC-Derived Tissue-Specific Cells." -to be presented by Taeyun Kim on May 10 from 12:00-7:00 pm, Targeted Gene Insertion Poster Session.
"Chromatin Opening Elements Mitigate Silencing of Transgenes During iPS Cell to Macrophage or Lymphocyte Differentiation." -to be presented by Claire Aibel on May 10 from 12:00-7:00 pm, Gene Targeting and Gene Correction New Technologies Poster Session.
"Targeted Insertion of HLA-E at the B2M Locus of mRNA-Reprogrammed iPSCs Facilitates the Development of Allogenic Cell Therapies with Enhanced Safety Features." -to be presented by Elizabeth Belcher on May 10 from 12:00-7:00 pm, Targeted Gene Insertion Poster Session.
"iPS-Derived Macrophages Engineered to Express IL-12 Enhance Cancer Cell Killing of a Multi-Cell Type Therapeutic Platform." -to be presented by Ian Hay on May 10 from 12:00-7:00 pm, Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies Poster Session.
"A Library of Novel Polyvalent Ionizable Lipids for Targeted Co-Delivery of mRNA and DNA." -to be presented by Joey Pisano, Ph.D. on May 10 from 12:00-7:00 pm, Nonviral Therapeutic Gene Delivery and Synthetic/Molecular Conjugates Poster Session.
"Novel Polyvalent Ionizable Lipids Enable Targeted Delivery of mRNA to T Cells and Monocytes." -to be presented by Ariadna Lubinus on May 10 from 12:00-7:00 pm, Nonviral Therapeutic Gene Delivery and Synthetic/Molecular Conjugates Poster Session.
For more information about the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting, visit annualmeeting.asgct.org.